Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Eli Lilly Stock: Is LLY Underperforming the Healthcare Sector?

With a market cap of $694.9 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876, it is renowned for developing innovative medicines in areas such as diabetes, oncology, immunology, neuroscience, and obesity management. 

Companies valued over $200 billion are generally described as “mega-cap” stocks, and Eli Lilly fits right into that category. The company has a strong research and development focus, investing heavily in next-generation biologics, oncology therapies, and treatments for neurodegenerative diseases such as Alzheimer’s. It is also expanding in immunology and rare diseases through acquisitions and strategic collaborations.

Fundamentals

See More
  • Market Capitalization, $K 693,355,456
  • Shares Outstanding, K 946,457
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ 16,802 M
  • EBITDA $ 18,569 M
  • 60-Month Beta 0.44
  • Price/Sales 15.38
  • Price/Cash Flow 51.42
  • Price/Book 37.81

Options Overview Details

View History
  • Implied Volatility 27.09% ( -1.28%)
  • Historical Volatility 56.48%
  • IV Percentile 7%
  • IV Rank 7.56%
  • IV High 64.53% on 04/07/25
  • IV Low 24.03% on 08/30/24
  • Put/Call Vol Ratio 1.07
  • Today's Volume 72,043
  • Volume Avg (30-Day) 114,734
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 510,815
  • Open Int (30-Day) 474,030

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate 6.42
  • Number of Estimates 9
  • High Estimate 7.51
  • Low Estimate 5.59
  • Prior Year 1.18
  • Growth Rate Est. (year over year) +444.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
623.78 +17.44%
on 08/08/25
778.10 -5.85%
on 07/30/25
-30.37 (-3.98%)
since 07/29/25
3-Month
623.78 +17.44%
on 08/08/25
825.00 -11.20%
on 06/16/25
+10.01 (+1.39%)
since 05/29/25
52-Week
623.78 +17.44%
on 08/08/25
969.65 -24.45%
on 09/03/24
-216.36 (-22.80%)
since 08/28/24

Most Recent Stories

More News
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?

Merck MRK and AbbVie ABBV are prominent pharmaceutical companies with strong positions in oncology and immunology.AbbVie also operates in aesthetics, neuroscience and eye care, while Merck has a broader...

JNJ : 177.17 (+0.98%)
MRK : 84.12 (+1.09%)
LLY : 732.58 (+0.08%)
ABBV : 210.40 (+1.19%)
Eli Lilly Stock: Is LLY Underperforming the Healthcare Sector?

Although Eli Lilly has trailed the broader healthcare sector over the past year, analysts maintain a strongly bullish outlook on the stock’s long-term growth potential.

XLV : 137.43 (+0.73%)
JNJ : 177.17 (+0.98%)
LLY : 732.58 (+0.08%)
Get a FREE 1-Year Subscription to Barchart Premier! Open and Fund a Plus500 Futures Account and Make a Trade

Barchart Premier provides futures traders with historical data, advanced charting, watchlists, & screeners to help make smarter decisions. Join 30M+ people worldwide who use Plus500!

Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?

Pfizer PFE is likely to encounter several headwinds in the next couple of years that can hurt its sales and profits, the first being its upcoming loss of exclusivity (“LOE”) cliff.Though Pfizer expects...

JNJ : 177.17 (+0.98%)
MRK : 84.12 (+1.09%)
LLY : 732.58 (+0.08%)
PFE : 24.76 (+0.65%)
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to...

LLY : 732.58 (+0.08%)
What Is the Intent Behind AbbVie's Recent Acquisition Spree?

AbbVie ABBV has been on an acquisition spree in the past couple of years to bolster the early-stage pipeline, which should drive long-term growth. Though immunology remains its core area, the company...

JNJ : 177.17 (+0.98%)
LLY : 732.58 (+0.08%)
ABBV : 210.40 (+1.19%)
LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?

Eli Lilly & Company LLY and Pfizer PFE are both large-cap U.S. pharmaceutical giants with diversified drug portfolios and strong R&D pipelines. While Lilly boasts a leading presence in cardiometabolic...

NVO : 56.46 (+0.62%)
LLY : 732.58 (+0.08%)
PFE : 24.76 (+0.65%)
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone

LLY : 732.58 (+0.08%)
Nasdaq Futures Tread Water With Nvidia Earnings in Focus

September Nasdaq 100 E-Mini futures (NQU25) are trending up +0.02% this morning, with investors in wait-and-see mode ahead of a highly anticipated earnings report from AI darling Nvidia.

A : 125.66 (+0.56%)
CRWD : 423.70 (-4.14%)
NQU25 : 23,461.75s (-1.29%)
SNOW : 238.66 (-0.97%)
CBRL : 59.82 (-0.40%)
VEEV : 269.20 (-1.15%)
HPQ : 28.54 (+0.67%)
DNUT : 3.55 (-0.42%)
MDB : 315.61 (-0.78%)
OKTA : 92.77 (+0.19%)
NCNO : 32.11 (+0.03%)
QCOM : 160.73 (-0.04%)
Durable Goods Orders Decreased Less Than Expected

Pre-market activity is somewhat better than earlier in the trading session this morning, following a less-bad Durable Goods report for July. We also appear to be bouncing around a bit more in recent trading...

BMO : 121.00 (+1.51%)
BNS : 62.46 (+0.11%)
LLY : 732.58 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 746.09
2nd Resistance Point 741.75
1st Resistance Point 737.17
Last Price 732.58
1st Support Level 728.25
2nd Support Level 723.91
3rd Support Level 719.33

See More

52-Week High 969.65
Fibonacci 61.8% 837.53
Fibonacci 50% 796.71
Fibonacci 38.2% 755.90
Last Price 732.58
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar